<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0309234096
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ARENA PLUS 300 mg/25 mg Film Coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        IRBESARTAN,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300,25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        55.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09CA04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Arena&trade; Plus is a combination of two active substances, irbesartan and hydrochlorothiazide. Irbesartan belongs to a group of medicines known as angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body that binds to receptors in blood vessels causing them to tighten. This results in an increase in blood pressure. Irbesartan prevents the binding of angiotensin-II to these receptors, causing the blood vessels to relax and the blood pressure to lower.</p><p dir="ltr">Hydrochlorothiazide is one of a group of medicines (called thiazide diuretics) that causes increased urine output and so causes a lowering of blood pressure.</p><p dir="ltr">The two active ingredients in Arena&trade; Plus work together to lower blood pressure further than if either was given alone.</p><p dir="ltr"><strong>Arena&trade; Plus is used to treat high blood pressure, </strong>when treatment with irbesartan or hydrochlorothiazide alone did not provide adequate control of your blood pressure.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Do not take Arena&trade; Plus</strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to irbesartan or any of the other ingredients of this medicine (listed in section 6)</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to hydrochlorothiazide or any other sulfonamide-derived medicines</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are more than 3 months pregnant. (It is also better to avoid Arena&trade; Plus in early pregnancy &ndash; see pregnancy section)</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver or kidney problems</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have difficulty in producing urine</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if your doctor determines that you have persistently high calcium or low potassium levels in your blood</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Warnings and precautions</strong></p><p dir="ltr">Talk to your doctor before taking Arena&trade; Plus and if any of the following apply to you:</p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Choroidal effusion, acute myopia and secondary angle-closure glaucoma:</p><p dir="ltr">Sulfonamide or sulfonamide derivative drugs can cause an idiosyncratic reaction resulting in choroidal effusion with visual field defect, transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.</p><p dir="ltr">&bull; if you get excessive vomiting or diarrhoea</p><p dir="ltr">&bull; if you suffer from kidney problems or have a kidney transplant</p><p dir="ltr">&bull; if you suffer from heart problems</p><p dir="ltr">&bull; if you suffer from liver problems</p><p dir="ltr">&bull; if you suffer from diabetes</p><p dir="ltr">&bull; if you suffer from lupus erythematosus (also known as lupus or SLE)</p><p dir="ltr">&bull; if you suffer from primary aldosteronism (a condition related to high production of the hormone aldosterone, which causes sodium retention and, in turn, an increase in blood pressure).</p><p dir="ltr">&bull; if you are taking any of the following medicines used to treat high blood pressure:</p><p dir="ltr">- an ACE-inhibitor (for example enalapril, lisinopril, ramipiril), in particular if you have diabetes-related kidney problems.</p><p dir="ltr">- aliskiren.</p><p dir="ltr">Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p dir="ltr">See also information under the heading &ldquo;Do not take Arena&trade; Plus&rdquo;.</p><p dir="ltr">You must tell your doctor if you think you are (or might become) pregnant. Arena&trade; Plus is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage (see pregnancy section).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>You should also tell your doctor:</strong></p><p dir="ltr">&bull; if you are on a low-salt diet</p><p dir="ltr">&bull; if you have signs such as abnormal thirst, dry mouth, general weakness, drowsiness, muscle pain or cramps, nausea, vomiting, or an abnormally fast heart beat which may indicate an excessive effect of hydrochlorothiazide (contained in Arena&trade; Plus)</p><p dir="ltr">&bull; if you experience an increased sensitivity of the skin to the sun with symptoms of sunburn (such as redness, itching, swelling, blistering) occurring more quickly than normal</p><p dir="ltr">&bull; if you are going to have an operation (surgery) or be given anaesthetics</p><p dir="ltr">&bull; if you have changes in your vision or pain in one or both of your eyes while taking Arena&trade; Plus. This could be a sign that you are developing glaucoma, increased pressure in your eye(s).</p><p dir="ltr">You should discontinue Arena&trade; Plus treatment and seek medical attention.</p><p dir="ltr">The hydrochlorothiazide contained in this medicine could produce a positive result in an anti-doping test.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Children and adolescents</strong></p><p dir="ltr">Arena&trade; Plus should not be given to children and adolescents (under 18 years).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Other medicines and Arena&trade; Plus</strong></p><p dir="ltr">Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p dir="ltr">Diuretic agents such as the hydrochlorothiazide contained in Arena&trade; Plus may have an effect on other medicines. Preparations containing lithium should not be taken with Arena&trade; Plus without close supervision by your doctor.</p><p dir="ltr">Your doctor may need to change your dose and/or to take other precautions:</p><p dir="ltr">If you are taking an ACE-inhibitor or aliskiren (see also information under the headings &ldquo;Do not take Arena&trade; Plus&rdquo; and &ldquo;Warnings and precautions&rdquo;).</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>You may need to have blood checks if you take:</strong></p><p dir="ltr">&bull; potassium supplements</p><p dir="ltr">&bull; salt substitutes containing potassium</p><p dir="ltr">&bull; potassium sparing medicines or other diuretics (water tablets)</p><p dir="ltr">&bull; some laxatives</p><p dir="ltr">&bull; medicines for the treatment of gout</p><p dir="ltr">&bull; therapeutic vitamin D supplements</p><p dir="ltr">&bull; medicines to control heart rhythm</p><p dir="ltr">&bull; medicines for diabetes (oral agents or insulins)</p><p dir="ltr">&bull; carbamazepine (a medicine for the treatment of epilepsy).</p><p dir="ltr">It is also important to tell your doctor if you are taking other medicines to reduce your blood pressure, steroids, medicines to treat cancer, pain killers, arthritis medicines, or colestyramine and colestipol resins for lowering blood cholesterol.</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>Arena&trade; Plus with food and drink</strong></p><p dir="ltr">Arena&trade; Plus can be taken with or without food.</p><p dir="ltr">Due to the hydrochlorothiazide contained in Arena&trade; Plus, if you drink alcohol while on treatment with this medicine, you may have an increased feeling of dizziness on standing up, specially when getting up from a sitting position.</p><p dir="ltr"><strong>Pregnancy and breast-feeding</strong></p><p dir="ltr"><strong>Pregnancy</strong></p><p dir="ltr">You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking Arena&trade; Plus before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of Arena&trade; Plus. Arena&trade; Plus is not recommended in early pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if used after the third month of pregnancy.</p><p dir="ltr"><strong>Breast-feeding</strong></p><p dir="ltr">Tell your doctor if you are breast-feeding or about to start breastfeeding.</p><p dir="ltr">Arena&trade; Plus is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed, especially if your baby is newborn, or was born prematurely.</p><p dir="ltr"><strong>Driving and using machines</strong></p><p dir="ltr">No studies on the effects on the ability to drive and use machines have been performed. Arena&trade; Plus is unlikely to affect your ability to drive or use machines. However, occasionally dizziness or weariness may occur during treatment of high blood pressure. If you experience these, talk to your doctor before attempting to drive or use machines.</p><p dir="ltr">Arena&trade; Plus contains lactose. If you have been told by your doctor that you have an intolerance to some sugars (e.g. lactose), contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p dir="ltr"><strong>Dosage</strong></p><p dir="ltr">The recommended dose of Arena&trade; Plus is one or two tablets a day.</p><p dir="ltr">Arena&trade; Plus will usually be prescribed by your doctor when your previous treatment did not reduce your blood pressure enough. Your doctor will instruct you how to switch from the previous treatment to Arena&trade; Plus.</p><p dir="ltr"><strong>Method of administration</strong></p><p dir="ltr">Arena&trade; Plus is for oral use. Swallow the tablets with a sufficient amount of fluid (e.g. one glass of water). You can take Arena&trade; Plus with or without food. Try to take your daily dose at about the same time each day.</p><p dir="ltr">It is important that you continue to take Arena&trade; Plus until your doctor tells you otherwise.</p><p dir="ltr">The maximal blood pressure lowering effect should be reached 6-8 weeks after beginning treatment.</p><p dir="ltr"><strong>If you take more Arena&trade; Plus than you should</strong></p><p dir="ltr">If you accidentally take too many tablets, contact your doctor immediately.</p><p dir="ltr"><strong>Children should not take Arena&trade; Plus</strong></p><p dir="ltr">Arena&trade; Plus should not be given to children under 18 years of age. If a child swallows some tablets, contact your doctor immediately.</p><p dir="ltr"><strong>If you forget to take Arena&trade; Plus</strong></p><p dir="ltr">If you accidentally miss a daily dose, just take the next dose as normal.</p><p dir="ltr">Do not take a double dose to make up for a forgotten dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Like all medicines, this medicine can cause side effects, although not everybody gets them. Some of these effects may be serious and may require medical attention.</p><p dir="ltr">Rare cases of allergic skin reactions (rash, urticaria), as well as localized swelling of the face, lips and/or tongue have been reported in patients taking irbesartan.</p><p dir="ltr">If you get any of the above symptoms or get short of breath, stop taking Arena&trade; Plus and contact your doctor immediately.</p><p dir="ltr">The frequency of the side effects listed below is defined using the following convention:</p><p dir="ltr">Common: may affect up to 1 in 10 people</p><p dir="ltr">Uncommon: may affect up to 1 in 100 people</p><p dir="ltr"><strong>Side effects reported in clinical studies for patients treated with</strong></p><p dir="ltr"><strong>Irbesartan and Hydrochlorothiazide were:</strong></p><p dir="ltr"><strong>Common side effects (may affect up to 1 in 10 people):</strong></p><p dir="ltr">&bull; nausea/vomiting</p><p dir="ltr">&bull; abnormal urination</p><p dir="ltr">&bull; fatigue</p><p dir="ltr">&bull; dizziness (including when getting up from a lying or sitting position)</p><p dir="ltr">&bull; blood tests may show raised levels of an enzyme that measures the muscle and heart function (creatine kinase) or raised levels of substances that measure kidney function (blood urea nitrogen, creatinine).</p><p dir="ltr">If any of these side effects causes you problems, talk to your doctor.</p><p dir="ltr"><strong>Uncommon side effects (may affect up to 1 in 100 people):</strong></p><p dir="ltr">&bull; diarrhoea</p><p dir="ltr">&bull; low blood pressure</p><p dir="ltr">&bull; fainting</p><p dir="ltr">&bull; heart rate increased</p><p dir="ltr">&bull; flushing</p><p dir="ltr">&bull; swelling</p><p dir="ltr">&bull; sexual dysfunction (problems with sexual performance)</p><p dir="ltr">&bull; blood tests may show lowered levels of potassium and sodium in your blood.</p><p dir="ltr">If any of these side effects causes you problems, talk to your doctor.</p><p dir="ltr"><strong>Side effects reported since the launch of (irbesartan/hydrochlorothiazide)</strong></p><p dir="ltr">Some undesirable effects have been reported since marketing of (irbesartan/ hydrochlorothiazide). Undesirable effects where the frequency is not known are: headache, ringing in the ears, cough, taste disturbance, indigestion, pain in joints and muscles, liver function abnormal and impaired kidney function, increased level of potassium in your blood and allergic reactions such as rash, hives, swelling of the face, lips, mouth, tongue or throat. Uncommon cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been reported.</p><p dir="ltr">As for any combination of two active substances, side effects associated with each individual component cannot be excluded.</p><p dir="ltr"><strong>Side effects associated with irbesartan alone</strong></p><p dir="ltr">In addition to the side effects listed above, chest pain has also been reported.</p><p dir="ltr"><strong>Side effects associated with hydrochlorothiazide alone</strong></p><p dir="ltr">Loss of appetite; stomach irritation; stomach cramps; constipation; jaundice (yellowing of the skin and/or whites of the eyes); inflammation of the pancreas characterised by severe upper stomach pain, often with nausea and vomiting; sleep disorders; depression; blurred vision; lack of white blood cells, which can result in frequent infections, fever; decrease in the number of platelets (a blood cell essential for the clotting of the blood), decreased number of red blood cells (anaemia) characterised by tiredness, headaches, being short of breath when exercising, dizziness and looking pale; kidney disease; lung problems including pneumonia or build-up of fluid in the lungs; increased sensitivity of the skin to the sun; inflammation of blood vessels; a skin disease characterized by the peeling of the skin all over the body; cutaneous lupus erythematosus, which is identified by a rash that may appear on the face, neck, and scalp; allergic reactions; weakness and muscle spasm; altered heart rate; reduced blood pressure after a change in body position; swelling of the salivary glands; high sugar levels in the blood; sugar in the urine; increases in some kinds of blood fat; high uric acid levels in the blood, which may cause gout.</p><p dir="ltr">Eye disorders; Choroidal effusion</p><p dir="ltr">Frequency: Unknown</p><p dir="ltr">Cases of choroidal effusion with visual field defect have been reported after the use of thiazide and thiazide-like diuretics. If cases are to be reported for these substances in the future, the appropriate procedure should be used to update the product information accordingly.</p><p dir="ltr">It is known that side effects associated with hydrochlorothiazide may increase with higher doses of hydrochlorothiazide.</p><p dir="ltr">If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr">Keep out of reach and sight of children.</p><p dir="ltr">Do not store above 30 &deg;C.</p><p dir="ltr">Store in the original package in order to protect from moisture.</p><p dir="ltr">Do not use this medicine after the expiry date which is stated on the carton and on the blister after EXP.</p><p dir="ltr">Do not throw away any medicines via wastewater or household waste.</p><p dir="ltr">Ask your pharmacist how to throw away medicines you no longer use.</p><p dir="ltr">These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>What Arena&trade; Plus contains</strong></p><p dir="ltr">&bull; <strong>The active substances </strong>are Irbesartan and Hydrochlorothiazide.</p><p dir="ltr">Arena&trade; Plus 150/12.5 mg: Each tablet contains 150 mg irbesartan and</p><p dir="ltr">12.5 mg hydrochlorothiazide.</p><p dir="ltr">Arena&trade; Plus 300/12.5 mg: Each tablet contains 300 mg irbesartan and</p><p dir="ltr">12.5 mg hydrochlorothiazide.</p><p dir="ltr">Arena&trade; Plus 300/25 mg: Each tablet contains 300 mg irbesartan and</p><p dir="ltr">25 mg hydrochlorothiazide.</p><p dir="ltr">&nbsp;</p><p dir="ltr">&bull; <strong>The other ingredients are:</strong></p><p dir="ltr">Core: Lactose Monohydrate, Microcrystalline Cellulose, Croscarmellose Sodium, Pregelatinized starch, Magnesium Stearate, In addition, Arena&trade; Plus 300/12.5 mg tablets contains Red iron oxide, Yellow iron oxide.</p><p dir="ltr">Coating: - Arena&trade; Plus 150/12.5mg and 300/12.5mg: Opadry II 32F240021 Pink (which consists of Hypromellose, Lactose Monohydrate, Titanium Dioxide, Polyethylene Glycol, Iron Oxide Yellow &amp; Iron Oxide Red).</p><p dir="ltr">- Arena&trade; Plus 300/25 mg: Opadry II 32F265003 Pink (which consists of Hypromellose, Lactose Monohydrate, Titanium Dioxide, Polyethylene Glycol, Iron Oxide Red &amp; Ferrosoferric Oxide).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Arena™ Plus 150/12.5 mg tablets: Peach, biconvex, oval-shaped with a debossed "114" on one side and "JP" on the other side.
Arena™ Plus 300/12.5 mg tablets: Peach, biconvex, oval-shaped with a debossed "116" on one side and "JP" on the other side.
Arena™ Plus 300/25 mg tablets: Pink, biconvex, oval-shaped with a debossed "133" on one side and "JP" on the other side.
Arena™ Plus film coated tablets are available in 150/12.5 mg, 300/12.5 mg and 300/25 mg in boxes of 30 tablets each.
Not all pack may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p dir="ltr"><strong>Marketing Authorization Holder and Manufacturer</strong></p><p dir="ltr">Jamjoom Pharmaceuticals Co., Jeddah, Saudi Arabia.</p><p dir="ltr">Tel: +966-12-6081111, Fax: +966-12-6081222</p><p dir="ltr">Website: www.jamjoompharma.com</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>To report any side effect(s):</strong></p><p dir="ltr">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p dir="ltr">Please report adverse drug events to:</p><p dir="ltr">The National Pharmacovigilance Centre (NPC):</p><p dir="ltr">Fax: +966-11-205-7662</p><p dir="ltr">SFDA Call Center: 19999</p><p dir="ltr">E-mail: npc.drug@sfda.gov.sa</p><p dir="ltr">Website: https://ade.sfda.gov.sa</p><p dir="ltr">&nbsp;</p><p dir="ltr"><strong>&bull; Other GCC States:</strong></p><p dir="ltr">&minus; Please contact the relevant competent authority.</p><p dir="ltr">&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                05/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>1.&nbsp;<strong>ما هو أرينا&trade; بلس وفيما يستخدم؟</strong><br />أرينا&trade; بلس يجمع بين مادتين فعالتين هما إربيسارتان وهيدروكلوروثيازيد.</p><p>إربيسارتان&nbsp;ينتمي إلى مجموعة من الأدوية تسمى &quot;مثبطات مستقبلات الأنجيوتنسين-II&quot;. الأنجيوتنسين-II هو مادة ينتجها الجسم ترتبط بمستقبلات موجودة في الأوعية الدموية فتجعلها تنقبض مما ينتج عنه ارتفاع في ضغط الدم. إربيسارتان يمنع ارتباط الأنجيوتنسين-II بهذه المستقبلات، مما يسبب تمدد هذه الأوعية وانخفاض ضغط الدم.</p><p>هيدروكلوروثيازيد&nbsp;ينتمي إلى مجموعة من الأدوية تسمى &quot;مدرات البول الثيازيدية&quot; والتي تسبب زيادة خروج البول، وبالتالي تؤدي إلى انخفاض ضغط الدم.</p><p>المادتان الفعالتان في أرينا&trade; بلس تعملان معًا لخفض ضغط الدم بشكل أكبر مما يحققه أحدهما وحده.</p><p>أرينا&trade; بلس يستخدم لعلاج ضغط الدم المرتفع&nbsp;عندما لا يقدم العلاج المنفرد بإربيسارتان أو هيدروكلوروثيازيد السيطرة الكافية على ضغط الدم.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>2. ما&nbsp;الذي تحتاج لمعرفته قبل أن تأخذ أرينا&trade; بلس؟</strong><br />لا تأخذ أرينا&trade; بلس في الحالات الآتية:<br />&bull; إذا كنت تعاني من حساسية مفرطة لإربيسارتان أو أي من المكونات الأخرى لهذا الدواء والمذكورة في الجزء رقم 6 من هذه النشرة.<br />&bull; إذا كنت تعاني من حساسية مفرطة لهيدروكلوروثيازيد أو أي من مشتقات السلفوناميد الأخرى.<br />&bull; بعد الشهر الثالث من الحمل. من المفضل أيضًا ألا يستخدم أرينا&trade; بلس في المرحلة الأولى من الحمل (انظر إلى الجزء الخاص بالحمل في هذه النشرة).<br />&bull; إذا كانت لديك مشاكل شديدة في الكبد أو الكلى.<br />&bull; إذا كانت لديك مشاكل في إنتاج البول.<br />&bull; إذا أخبرك طبيبك أنك تعاني من استمرار ارتفاع مستويات الكالسيوم أو انخفاض مستويات البوتاسيوم في الدم.<br />&bull; إذا كان لديك مرض السكري أو اختلال في وظائف الكلى وكنت تعالج بأدوية خافضة للضغط تحتوي على أليسكيرين.</p><p><strong>تحذيرات واحتياطات</strong><br />تحدث إلى طبيبك قبل أن تأخذ أرينا&trade; بلس إذا كان أي من الحالات الآتية ينطبق عليك:<br />&bull; انصباب المشيمية وقصر النظر الحاد وزرق إغلاق الزاوية الثانوي:<br />يمكن أن تسبب أدوية السلفوناميد أو الأدوية المشتقة من السلفوناميد في حدوث تفاعل غير طبيعي يؤدي إلى انصباب المشيمية مع عيب المجال البصري، وقصر النظر العابر وزرق إغلاق الزاوية الحاد. تشمل الأعراض البداية الحادة في انخفاض حدة البصر أو ألم العين وعادة ما تحدث في غضون ساعات إلى أسابيع من بدء الدواء. يمكن أن يؤدي زرق إغلاق الزاوية الحاد غير المعالج إلى فقدان الرؤية الدائم. العلاج الأساسي هو التوقف عن تناول الدواء في أسرع وقت ممكن. قد يلزم النظر في العلاجات الطبية أو الجراحية العاجلة إذا ظل ضغط العين غير منضبط. قد تشمل عوامل الخطر لتطوير الجلوكوما الحاد إغلاق الزاوية تاريخًا من حساسية السلفوناميد أو البنسلين.</p><p>&bull; إذا عانيت من إسهال أو قيء شديد.<br />&bull; إذا كنت تعاني من مشاكل في الكلى أو قمت بعملية زرع كلية.<br />&bull; إذا كنت تعاني من مشاكل في القلب.<br />&bull; إذا كنت تعاني من مشاكل في الكبد.<br />&bull; إذا كنت مصابًا بمرض السكري.<br />&bull; إذا كنت مصابًا بمرض الذئبة الحمراء.<br />&bull; إذا كنت تعاني من الارتفاع الأولي لهرمون الألدوستيرون وهي حالة يزداد فيها إنتاج هرمون الألدوستيرون والذي يسبب احتباس الصوديوم ونتيجة لذلك يرتفع ضغط الدم.<br />&bull; إذا كنت تأخذ أي من الأدوية التالية التي تستخدم لعلاج ارتفاع ضغط الدم:</p><ul><li><p>مثبطات الإنزيم المحول للأنجيوتنسين (ACE-inhibitors) (على سبيل المثال إنالابريل، ليزينوبريل، راميبريل)، ولا سيما إذا كان لديك مشاكل في الكلى المتصلة بالسكري.</p></li><li><p>أليسكيرين.</p></li></ul><p>طبيبك قد يتحقق من وظائف الكلية الخاصة بك وضغط الدم، وكمية الشوارد (مثل البوتاسيوم) في الدم على فترات منتظمة.<br />انظر أيضًا المعلومات تحت عنوان &quot;لا تأخذ أرينا&trade; بلس في الحالات الآتية.&quot;:</p><p>يجب أن تخبري طبيبك إذا كنت تشكين في كونك حاملاً أو قد تصبحين حاملاً. لا يوصى باستخدام أرينا&trade; بلس في مراحل الحمل الأولى ولا يجب استخدامه بعد مرور الأشهر الثلاثة الأولى من الحمل، لأنه قد يسبب ضررًا شديدًا لطفلك إذا تم استخدامه في هذه المرحلة (أنظر إلى الجزء الخاص بالحمل في هذه النشرة).</p><p><strong>يجب أيضًا أن تخبر طبيبك في الحالات التالية:</strong><br />&bull; إذا كنت تتبع نظامًا غذائيًا قليل الملح.<br />&bull; إذا كنت تعاني من بعض الأعراض مثل عطش غير عادي، جفاف الفم، الضعف العام، خمول، قيء، ألم في العضلات وتشنجات، غثيان، قيء، ضربات قلب سريعة مما قد يشير لحدوث زيادة في مفعول هيدروكلوروثيازيد الموجود في أرينا&trade; بلس.<br />&bull; زيادة حساسية الجلد للشمس مع ظهور أعراض حروق الشمس مثل احمرار، حكة، تورم أو تقشر والتي تحدث بسرعة أكبر من المعتاد.<br />&bull; سوف تجري عملية جراحية أو سوف تخضع لتخدير ما.<br />&bull; تعاني من تغير في الرؤية أو من ألم في إحدى العينين أو كلتيهما أثناء استخدامك لأرينا&trade; بلس قد يكون هذا علامة على إصابتك بالجلوكوما (المياه الزرقاء) أو زيادة ضغط العين. في هذه الحالة يجب أن توقف استخدام أرينا&trade; بلس وتطلب الرعاية الصحية.</p><p>هذا الدواء يحتوي على مادة فعالة (هيدروكلوروثيازيد) قد تعطي نتائج إيجابية في اختبارات الكشف عن المنشطات.</p><p><strong>الأطفال والمراهقين</strong><br />لا ينبغي إعطاء أرينا&trade; بلس للأطفال والمراهقين (تحت 18 عامًا).</p><p><strong>تعاطي أدوية أخرى</strong><br />يرجى إخبار الطبيب أو الصيدلي إذا كنت تأخذ أو أخذت مؤخرًا أي أدوية أخرى.<br />المواد المدرة للبول مثل هيدروكلوروثيازيد الموجودة في هذا الدواء قد تؤثر على بعض الأدوية الأخرى. لا يجب تعاطي المستحضرات المحتوية على الليثيوم مع أرينا&trade; بلس إلا تحت إشراف طبيبك المباشر.</p><p>قد يحتاج طبيبك لتغيير الجرعة و/أو اتخاذ الاحتياطات الأخرى:<br />إذا كنت تأخذ مثبطات الإنزيم المحول للأنجيوتنسين (ACE-inhibitors) أو أليسكيرين (انظر أيضًا المعلومات تحت عناوين &quot;لا تأخذ أرينا&trade; بلس في الحالات الآتية&quot;: و&quot;التحذيرات والاحتياطات.&quot;)</p><p>قد تحتاج إلى القيام ببعض الفحوصات الطبية إذا كنت تأخذ الآتي:<br />&bull; مكملات البوتاسيوم.<br />&bull; بدائل الملح المحتوية على البوتاسيوم.<br />&bull; الأدوية الحافظة للبوتاسيوم أو مدرات البول الأخرى.<br />&bull; بعض المليّنات.<br />&bull; أدوية علاج النقرس.<br />&bull; مكملات فيتامين د.<br />&bull; الأدوية المستخدمة للسيطرة على انتظام ضربات القلب.<br />&bull; الأدوية المستخدمة لعلاج مرض السكري مثل الأنسولين أو الأدوية التي تؤخذ عن طريق الفم.<br />&bull; الكاربامازيبين وهو دواء لعلاج الصرع.</p><p>من المهم أيضًا أن تخبر طبيبك إذا كنت تأخذ:<br />&bull; أي أدوية أخرى لخفض ضغط الدم.<br />&bull; ستيرويدات.<br />&bull; أدوية لعلاج السرطان.<br />&bull; المسكنات.<br />&bull; أدوية التهاب المفاصل.<br />&bull; راتنجات الكوليستيرامين والكوليستيبول المستخدمة لخفض مستوى الكوليسترول في الدم.</p><p><strong>تناول أرينا&trade; بلس مع الطعام والشراب</strong><br />يمكن أخذ أرينا&trade; بلس مع أو بدون الطعام.<br />نظرًا لوجود هيدروكلوروثيازيد في هذا الدواء، إذا كنت تشرب الكحول أثناء تعاطيك هذا الدواء، قد يزداد شعورك بالدوار عند الوقوف وخاصة عند النهوض من الجلوس.</p><p><strong>الحمل والرضاعة</strong><br /><strong>الحمل</strong><br />يجب أن تخبري طبيبك إذا كنت تشكين في كونك حاملاً أو قد تصبحين حاملاً. سوف ينصحك طبيبك بأن تتوقفي عن تناول أرينا&trade; بلس قبل أن تصبحي حاملاً أو بمجرد علمك بحدوث الحمل وسوف ينصحك بتناول دواء آخر. لا يوصى باستخدام أرينا&trade; بلس في الأشهر الأولى من الحمل ولا ينبغي أخذه إذا كنت حاملاً لأكثر من ثلاثة أشهر لأنه قد يسبب أذى خطيرًا لطفلك إذا استعمل في هذه المرحلة.</p><p><strong>الرضاعة</strong><br />يجب أن تخبري الطبيب إذا كنتي ترضعين طفلك طبيعيًا أو على وشك البدء في الرضاعة الطبيعية. لا يوصى باستخدام أرينا&trade; بلس للأمهات اللائي يرضعن أطفالهن طبيعيًا، وقد يختار طبيبك دواء آخر إذا كنتي ترغبين بالرضاعة الطبيعية خاصة إذا كان رضيعك حديث الولادة أو ولد غير مكتمل النمو.</p><p><strong>قيادة المركبات وتشغيل الآلات</strong><br />لا توجد دراسات توضح تأثير هذا الدواء على القدرة على القيادة أو استخدام الآلات. لكن، في بعض الأحيان قد يحدث دوار وتعب أثناء علاج ضغط الدم المرتفع. إذا حدث لك هذا، تحدث إلى طبيبك قبل قيامك بالقيادة أو استخدام أي آلات.</p><p><strong>أرينا&trade; بلس يحتوي على اللاكتوز. </strong>إذا قيل لك أنه لا يمكنك هضم بعض السكريات، أخبر طبيبك بهذا قبل البدء في تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>3. كيف تأخذ أرينا&trade; بلس</strong></p><p>قم دائمًا بأخذ أرينا&trade; بلس كما أخبرك طبيبك تمامًا. يجب عليك مراجعة الطبيب أو الصيدلي إذا كنت غير متأكد من طريقة الاستخدام.</p><p><strong>الجرعة</strong></p><ul><li><p>الجرعة الموصى بها لأرينا&trade; بلس هي قرص أو قرصين يوميًا.</p></li><li><p>سوف يتم وصف أرينا&trade; بلس لك من قبل طبيبك إذا كان علاجك السابق لا يخفض ضغط دمك بشكل كافٍ.</p></li><li><p>سوف يرشدك طبيبك كيف تنتقل من علاجك السابق إلى أرينا&trade; بلس.</p></li></ul><p><strong>طريقة الاستخدام</strong><br />أرينا&trade; بلس يؤخذ عن طريق الفم. قم ببلع الأقراص مع كمية كافية من الماء (على سبيل المثال كوب واحد من الماء). يمكنك أخذ أرينا&trade; بلس مع أو بدون الطعام. حاول أن تأخذ جرعتك اليومية يوميًا في نفس الموعد. من المهم أن تستمر في أخذ أرينا&trade; بلس حتى يطلب منك طبيبك أن تتوقف. يجب الوصول إلى أقصى مفعول خافض لضغط الدم بعد 6-8 أسابيع من بدء العلاج.</p><p><strong>إذا كنت تأخذ أرينا&trade; بلس أكثر مما ينبغي:</strong><br />إذا أخذت العديد من أقراص أرينا&trade; بلس عن طريق الخطأ، اتصل بطبيبك على الفور.</p><p><strong>لا يجب أن يأخذ الأطفال أرينا&trade; بلس</strong><br />لا يجب إعطاء أرينا&trade; بلس للأطفال تحت سن 18 عامًا. إذا قام طفل ببلع بعض الأقراص، اتصل بطبيبك على الفور.</p><p><strong>إذا نسيت أن تأخذ أرينا&trade; بلس:</strong><br />إذا نسيت أن تأخذ جرعة من أرينا&trade; بلس عن طريق الخطأ، قم فقط بأخذ جرعتك التالية كما هو معتاد. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p>إذا كانت لديك أي أسئلة عن استخدام هذا الدواء، يجب أن تستشير الطبيب.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;4. الآثار الجانبية المحتملة</strong></p><p>كما هو الحال مع جميع الأدوية، من المحتمل ظهور أعراض جانبية لأرينا&trade; بلس لكنها لا تصيب كل الأشخاص. قد تصبح بعض هذه الآثار خطيرة وقد تتطلب عناية طبية.</p><p>قد تم الإبلاغ عن حدوث بعض الحالات النادرة من تفاعلات حساسية الجلد مثل الطفح الجلدي وكذلك تورم موضعي في الوجه، الشفتين و/أو اللسان لدى المرضى الذين يتناولون إربيسارتان.<br />إذا عانيت من إحدى الأعراض المذكورة بالأعلى أو من ضيق في التنفس، توقف عن تناول أرينا&trade; بلس واتصل بطبيبك على الفور.</p><p><strong>تردد الآثار الجانبية المذكورة أدناه يعرف باستخدام المصطلحات التالية:</strong></p><p>شائعة: قد تصيب ما يصل إلى 1 من كل 10 أشخاص</p><p>غير شائعة: قد تصيب ما يصل إلى 1 من كل 100 شخص</p><p><strong>الأعراض الجانبية التي تم الإبلاغ عنها في الدراسات السريرية التي أجريت على المرضى الذين تم علاجهم بأرينا&trade; بلس هي:</strong></p><p><strong>أعراض جانبية شائعة (قد تصيب ما يصل إلى 1 من كل 10 أشخاص):</strong></p><ul><li><p>غثيان، قيء</p></li><li><p>اضطراب في إخراج البول</p></li><li><p>إرهاق</p></li><li><p>دوار (عند النهوض من وضع الاستلقاء أو من الجلوس)</p></li><li><p>فحوصات الدم تظهر ارتفاع مستويات الإنزيم الذي يقيس وظيفة القلب والعضلات (كيناز الكرياتين) أو ارتفاع مستويات المواد التي تقيس وظيفة الكلى (نيتروجين اليوريا في الدم والكرياتينين)</p></li></ul><p>إذا سببت إحدى هذه الأعراض الجانبية مشكلة لديك، تحدث إلى طبيبك.</p><p><strong>أعراض جانبية غير شائعة (قد تصيب ما يصل إلى 1 من كل 100 شخص):</strong></p><ul><li><p>إسهال</p></li><li><p>انخفاض ضغط الدم</p></li><li><p>إغماء</p></li><li><p>زيادة معدل ضربات القلب</p></li><li><p>هبات ساخنة</p></li><li><p>تورم</p></li><li><p>ضعف جنسي (مشاكل في الأداء الجنسي)</p></li><li><p>فحوصات الدم قد تظهر انخفاض مستويات البوتاسيوم والصوديوم في الدم</p></li></ul><p>إذا سببت إحدى هذه الأعراض الجانبية مشكلة لديك، تحدث إلى طبيبك.</p><p><strong>الآثار الجانبية التي تم الإبلاغ عن حدوثها منذ بدء تسويق (إربيسارتان/هيدروكلوروثيازيد):</strong><br />تم الإبلاغ عن بعض الآثار الجانبية غير المرغوب فيها منذ البدء في تسويق (إربيسارتان/هيدروكلوروثيازيد).</p><p><strong>الآثار الجانبية التي تم الإبلاغ عن حدوثها وغير معروف مدى تكرار حدوثها هي:</strong><br />صداع، طنين في الأذن، كحة، اضطراب حاسة التذوق، عسر هضم، ألم المفاصل والعضلات، اضطراب وظائف الكبد والكلى، ارتفاع مستوى البوتاسيوم في الدم وحساسية تشمل طفح جلدي، تورم الوجه، الشفتين، الفم، اللسان أو الحلق. تم الإبلاغ عن حدوث حالات غير شائعة من اليرقان (اصفرار الجلد و/أو بياض العينين).</p><p>كما هو الحال مع جميع الأدوية التي تجمع ما&nbsp; بين مادتين&nbsp;فعالتين، لا يمكن استبعاد حدوث الآثار الجانبية التي تحدث مع أي منهما.</p><p><strong>الآثار الجانبية التي تحدث مع إربيسارتان فقط:</strong><br />بالإضافة إلى الآثار الجانبية المذكورة بالأعلى، قد تم الإبلاغ عن حدوث ألم في الصدر أيضًا.</p><p><strong>الآثار الجانبية التي تحدث مع هيدروكلوروثيازيد فقط:</strong><br />فقدان الشهية، تهيج المعدة، تقلصات المعدة، إمساك، يرقان (اصفرار الجلد و/أو بياض العينين)، التهاب البنكرياس الذي يتميز بألم شديد أعلى المعدة غالبًا ما يكون مصاحب بغثيان وقيء، اضطرابات النوم، اكتئاب، عدم وضوح الرؤية، نقص خلايا الدم البيضاء مما ينتج عنه الإصابة المتكررة بالعدوى، الحمى، انخفاض عدد الصفائح الدموية (خلايا دم ضرورية لتخثر الدم)، انخفاض عدد خلايا الدم الحمراء (فقر الدم وأعراضها هي الإرهاق، الصداع، ضيق التنفس عند القيام بالأنشطة الرياضية، الدوار وجلد شاحب اللون)، مرض الكلى، مشاكل في الرئتين تشمل الالتهاب الرئوي وتجمع السوائل في الرئتين، زيادة حساسية الجلد للشمس، التهاب الأوعية الدموية (وهو مرض جلدي يتميز بتقشر الجلد في جميع أنحاء الجسم)، الذئبة الحمراء الجلدية (وأعراضها تشمل طفح جلدي على الوجه، الرقبة وفروة الرأس)، حساسية، ضعف وتقلصات العضلات، تغير معدل ضربات القلب، انخفاض ضغط الدم عند حدوث تغير في وضعية الجسم، تورم الغدد اللعابية، ارتفاع مستويات السكر في الدم وفي البول، ارتفاع أنواع معينة من دهون الدم، ارتفاع مستويات حمض اليوريك في الدم مما قد يسبب النقرس.</p><p>اضطرابات العين؛ انصباب المشيمية التردد: غير معروف<br />تم الإبلاغ عن حالات انصباب المشيمية مع عيب المجال البصري بعد استخدام مدرات البول الثيازيدية وشبه الثيازيدية.</p><p>من المعروف أن الآثار الجانبية الناتجة عن تعاطي هيدروكلوروثيازيد قد تزداد مع الجرعات العالية من هيدروكلوروثيازيد.</p><p>إذا شعرت بإحدى الأعراض الجانبية، تحدث إلى الطبيب أو الصيدلي. هذا يشمل أي أعراض أخرى محتملة غير مذكورة في هذه النشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>&nbsp;5. كيف تقوم بحفظ أرينا&trade; بلس</strong></p><p>يحفظ بعيداً عن متناول ورؤية الأطفال.<br />يحفظ في درجة حرارة لا تزيد عن ۳۰ درجة مئوية. يحفظ في علبته الأصلية لحمايته من الرطوبة.<br />لا تأخذ هذا الدواء بعد انتهاء فترة الصلاحية المكتوبة على العلبة وعلى الشرائط.<br />اسأل الصيدلي عن طريقة التخلص من الأدوية التي لم تعد بحاجة إليها. لا ينبغي التخلص من الأدوية عبر إلقائها في بالوعات الصرف أو في مخلفات المنزل. ستساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>٦. محتويات العبوة ومعلومات أخرى.</strong></p><p><strong>مما يتكون أرينا&trade; بلس</strong><br />المادتان الفعالتان هما إربيسارتان وهيدروكلوروثيازيد.</p><p>كل قرص من أرينا&trade; بلس 150 ملجم/ 12.5 ملجم يحتوي على 150 ملجم إربيسارتان و 12.5 ملجم هيدروكلوروثيازيد.<br />كل قرص من أرينا&trade; بلس 300 ملجم/ 12.5 ملجم&nbsp;يحتوي على 300 ملجم إربيسارتان و 12.5 ملجم هيدروكلوروثيازيد.<br />كل قرص من أرينا&trade; بلس 300 ملجم/ 25 ملجم يحتوي على 300 ملجم إربيسارتان و 25 ملجم هيدروكلوروثيازيد.</p><p><strong>المكونات الأخرى:</strong><br />لب القرص: لاكتوز أحادي التميؤ، سليولوز دقيق التبلور، كروسكرملوز صوديوم، نشا مسسبق التجلتن، إستيارات الماغنسيوم بالإضافة إلى ذلك، تحتوي أقراص أرينا&trade; بلس 300 ملجم/ 12.5 ملجم على أكسيد الحديد الأحمر وأكسيد الحديد الأصفر.</p><p><strong>الغلاف:</strong></p><ul><li><p>أرينا&trade; بلس 150 ملجم/ 12.5ملجم، 300 ملجم/ 12.5ملجم: أوبراي II 32F240021 الوردي (الذي يتكون من هيبروميللوز، لاكتوز أحادي التميؤ، ثاني أكسيد التيتانيوم، بولي إثيلين جلايكول، أكسيد الحديد الأحمر وأكسيد الحديد الأصفر).</p></li><li><p>أرينا&trade; بلس 300 ملجم/ 25 ملجم: أوبراي II 32F265003 الوردي (الذي يتكون من هيبروميللوز، لاكتوز أحادي التميؤ،&nbsp;ثاني أكسيد التيتانيوم، بولي إثيلين جلايكول، أكسيد الحديد الأحمر وحديدوز الحديديك أكسيد).</p></li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما هو شكل أقراص أرينا&trade; بلس وما هو محتوى العلبة؟</strong></p><p>أقراص أرينا&trade; بلس 150 ملجم/ 12.5 ملجم: لونها لون الخوخ، محدبة الوجهين، بيضاوية الشكل، محفور على جانب واحد &quot;114&quot;، و &quot;JP&quot; على الجانب الآخر.<br />أقراص أرينا&trade; بلس 300 ملجم/ 12.5 ملجم: لونها لون الخوخ، محدبة الوجهين، بيضاوية الشكل، محفور على جانب واحد &quot;116&quot;، و &quot;JP&quot; على الجانب الآخر.<br />أقراص أرينا&trade; بلس 300 ملجم/ 25 ملجم: لونها وردي، محدبة الوجهين، بيضاوية الشكل، محفور على جانب واحد &quot;133&quot;، و &quot;JP&quot; على الجانب الآخر.</p><p>أرينا&trade; بلس أقراص مغلفة متوفر بتركيزات 150 ملجم/ 12.5ملجم، 300 ملجم/ 12.5ملجم، 300 ملجم/ 25 ملجم في عبوات تحتوي كل منها على 30 قرصاً.<br />قد لا تكون كل العبوات مطروحة بالسوق.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما هو شكل أقراص أرينا&trade; بلس وما هو محتوى العلبة؟</strong></p><p>أقراص أرينا&trade; بلس 150 ملجم/ 12.5 ملجم: لونها لون الخوخ، محدبة الوجهين، بيضاوية الشكل، محفور على جانب واحد &quot;114&quot;، و &quot;JP&quot; على الجانب الآخر.<br />أقراص أرينا&trade; بلس 300 ملجم/ 12.5 ملجم: لونها لون الخوخ، محدبة الوجهين، بيضاوية الشكل، محفور على جانب واحد &quot;116&quot;، و &quot;JP&quot; على الجانب الآخر.<br />أقراص أرينا&trade; بلس 300 ملجم/ 25 ملجم: لونها وردي، محدبة الوجهين، بيضاوية الشكل، محفور على جانب واحد &quot;133&quot;، و &quot;JP&quot; على الجانب الآخر.</p><p>أرينا&trade; بلس أقراص مغلفة متوفر بتركيزات 150 ملجم/ 12.5ملجم، 300 ملجم/ 12.5ملجم، 300 ملجم/ 25 ملجم في عبوات تحتوي كل منها على 30 قرصاً.<br />قد لا تكون كل العبوات مطروحة بالسوق.</p><p><strong>اسم وعنوان مالك رخصة التسويق والمصنع:</strong><br />شركة مصنع جمجوم للأدوية، جدة، المملكة العربية السعودية.</p><p>هاتف: +966-12-6081111&nbsp;فاكس:&nbsp;+966-12-6081222<br />الموقع الإلكتروني:&nbsp;www.jamjoompharma.com</p><p><strong>للإبلاغ عن أي آثار جانبية:</strong><br />&bull; المملكة العربية السعودية:<br />يرجى الإبلاغ عن الأحداث الدوائية الضارة إلى: المركز الوطني للتيقظ والسلامة الدوائية<br />فاكس: +966-11-2057662 الخط الساخن للإبلاغ: 1999<br />البريد الإلكتروني:&nbsp;npc.drug@sfda.gov.sa&nbsp;الموقع الإلكتروني:&nbsp;https://ade.sfda.gov.sa</p><p>&bull; دول الخليج الأخرى:</p><ul><li><p>الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.</p></li></ul>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            05/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Arena Plus 300 mg/25 mg Film Coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains 300 mg of Irbesartan and 25 mg of Hydrochlorothiazide.
Excipient with known effect:
Each film-coated tablet contains 55.00 mg of lactose monohydrate.
For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Pink, biconvex, oval-shaped table with "133" debossed on one side and "JP" on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension.<br />This fixed dose combination is indicated in adult patients whose blood pressure is not adequately<br />controlled on Irbesartan or hydrochlorothiazide alone (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Irbesartan and Hydrochlorothiazide can be taken once daily, with or without food.<br />Dose titration with the individual components (i.e. Irbesartan and hydrochlorothiazide) may be<br />recommended.<br />When clinically appropriate direct change from monotherapy to the fixed combinations may be<br />considered:<br /> Irbesartan and Hydrochlorothiazide 150 mg/12.5 mg may be administered in patients whose blood<br />pressure is not adequately controlled with hydrochlorothiazide or Irbesartan 150 mg alone;</p><p> Irbesartan and Hydrochlorothiazide300 mg/12.5 mg may be administered in patients insufficiently<br />controlled by Irbesartan 300 mg or by Irbesartan and Hydrochlorothiazide150 mg/12.5 mg.<br /> Irbesartan and Hydrochlorothiazide300 mg/25 mg may be administered in patients insufficiently<br />controlled by Irbesartan and Hydrochlorothiazide300 mg/12.5 mg.<br />Doses higher than 300 mg Irbesartan/25 mg hydrochlorothiazide once daily are not recommended.<br />When necessary, Irbesartan and Hydrochlorothiazide may be administered with another antihypertensive<br />medicinal product (see sections 4.3, 4.4, 4.5 and 5.1).<br />Special Populations<br />Renal impairment: due to the hydrochlorothiazide component, Irbesartan and Hydrochlorothiazide is not<br />recommended for patients with severe renal dysfunction (creatinine clearance &lt; 30 ml/min). Loop<br />diuretics are preferred to thiazides in this population. No dosage adjustment is necessary in patients with<br />renal impairment whose renal creatinine clearance is &ge; 30 ml/min (see sections 4.3 and 4.4).<br />Hepatic impairment: Irbesartan and Hydrochlorothiazide is not indicated in patients with severe hepatic<br />impairment. Thiazides should be used with caution in patients with impaired hepatic function. No dosage<br />adjustment of Irbesartan and Hydrochlorothiazide is necessary in patients with mild to moderate hepatic<br />impairment (see section 4.3).<br />Older people: no dosage adjustment of Irbesartan and Hydrochlorothiazide is necessary in older people.<br />Paediatric population: Irbesartan and Hydrochlorothiazide is not recommended for use in children and<br />adolescents because the safety and efficacy have not been established. No data are available.<br />Method of Administration<br />For oral use.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 Hypersensitivity to the active substances or to any of the excipients listed in section 6.1, or to other
sulfonamide-derived substances (hydrochlorothiazide is a sulfonamide-derived substance)
 Second and third trimesters of pregnancy (see sections 4.4 and 4.6)
 Severe renal impairment (creatinine clearance < 30 ml/min)
 Refractory hypokalaemia, hypercalcaemia
 Severe hepatic impairment, biliary cirrhosis and cholestasis
 The concomitant use of Irbesartan and Hydrochlorothiazide with aliskiren-containing products is
contraindicated in patients with diabetes mellitus or renal impairment (glomerular filtration rate
(GFR) <60 ml/min/1.73 m2) (see sections 4.5 and 5.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Hypotension - Volume-depleted patients: Irbesartan and Hydrochlorothiazide has been rarely associated<br />with symptomatic hypotension in hypertensive patients without other risk factors for hypotension.<br />Symptomatic hypotension may be expected to occur in patients who are volume and/or sodium depleted<br />by vigorous diuretic therapy, dietary salt restriction, diarrhoea or vomiting. Such conditions should be<br />corrected before initiating therapy with Irbesartan and Hydrochlorothiazide.<br />Renal artery stenosis - Renovascular hypertension: there is an increased risk of severe hypotension and<br />renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single<br />functioning kidney are treated with angiotensin converting enzyme inhibitors or angiotensin-II receptor<br />antagonists. While this is not documented with Irbesartan and Hydrochlorothiazide, a similar effect<br />should be anticipated.<br />Renal impairment and kidney transplantation: when Irbesartan and Hydrochlorothiazide is used in<br />patients with impaired renal function, a periodic monitoring of potassium, creatinine and uric acid serum<br />levels is recommended. There is no experience regarding the administration of Irbesartan and<br />Hydrochlorothiazide in patients with a recent kidney transplantation. Irbesartan and Hydrochlorothiazide<br />should not be used in patients with severe renal impairment (creatinine clearance &lt; 30 ml/min) (see<br />section 4.3). Thiazide diuretic-associated azotemia may occur in patients with impaired renal function.<br />No dosage adjustment is necessary in patients with renal impairment whose creatinine clearance is &ge; 30<br />ml/min. However, in patients with mild to moderate renal impairment (creatinine clearance &ge; 30 ml/min<br />but &lt; 60 ml/min) this fixed dose combination should be administered with caution.<br />Dual blockade of the renin-angiotensin-aldosterone system (RAAS):<br />There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or<br />aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute&nbsp;renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II<br />receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1). If dual blockade<br />therapy is considered absolutely necessary, this should only occur under specialist supervision and<br />subject to frequent close monitoring of renal function, electrolytes and blood pressure. ACE-inhibitors<br />and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic<br />nephropathy.<br />Hepatic impairment: thiazides should be used with caution in patients with impaired hepatic function or<br />progressive liver disease, since minor alterations of fluid and electrolyte balance may precipitate hepatic<br />coma. There is no clinical experience with Irbesartan and Hydrochlorothiazide in patients with hepatic<br />impairment.<br />Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy: as with other vasodilators,<br />special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic<br />cardiomyopathy.<br />Primary aldosteronism: patients with primary aldosteronism generally will not respond to<br />antihypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore,<br />the use of Irbesartan and Hydrochlorothiazide is not recommended.<br />Metabolic and endocrine effects: thiazide therapy may impair glucose tolerance. In diabetic patients<br />dosage adjustments of insulin or oral hypoglycemic agents may be required. Latent diabetes mellitus may<br />become manifest during thiazide therapy.<br />Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy;<br />however at the 12.5 mg dose contained in Irbesartan and Hydrochlorothiazide, minimal or no effects<br />were reported.<br />Hyperuricaemia may occur or frank gout may be precipitated in certain patients receiving thiazide<br />therapy.<br />Electrolyte imbalance: as for any patient receiving diuretic therapy, periodic determination of serum<br />electrolytes should be performed at appropriate intervals.<br />Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (hypokalaemia,<br />hyponatraemia, and hypochloremic alkalosis). Warning signs of fluid or electrolyte imbalance are&nbsp;dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular<br />fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea or vomiting.<br />Although hypokalaemia may develop with the use of thiazide diuretics, concurrent therapy with<br />Irbesartan may reduce diuretic-induced hypokalaemia. The risk of hypokalaemia is greatest in patients<br />with cirrhosis of the liver, in patients experiencing brisk diuresis, in patients who are receiving<br />inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids<br />or ACTH. Conversely, due to the Irbesartan component of Irbesartan and Hydrochlorothiazide<br />hyperkalaemia might occur, especially in the presence of renal impairment and/or heart failure, and<br />diabetes mellitus. Adequate monitoring of serum potassium in patients at risk is recommended.<br />Potassium-sparing diuretics, potassium supplements or potassium-containing salts substitutes should be<br />co-administered cautiously with Irbesartan and Hydrochlorothiazide (see section 4.5).<br />There is no evidence that Irbesartan would reduce or prevent diuretic-induced hyponatraemia. Chloride<br />deficit is generally mild and usually does not require treatment.<br />Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum<br />calcium in the absence of known disorders of calcium metabolism. Marked hypercalcaemia may be<br />evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for<br />parathyroid function.<br />Thiazides have been shown to increase the urinary excretion of magnesium, which may result in<br />hypomagnaesemia.<br />Lithium: the combination of lithium and Irbesartan and Hydrochlorothiazide is not recommended (see<br />section 4.5).<br />Anti-doping test: hydrochlorothiazide contained in this medicinal product could produce a positive<br />analytic result in an anti-doping test.<br />General: in patients whose vascular tone and renal function depend predominantly on the activity of the<br />renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying<br />renal disease, including renal artery stenosis), treatment with angiotensin converting enzyme inhibitors or<br />angiotensin-II receptor antagonists that affect this system has been associated with acute hypotension,<br />azotemia, oliguria, or rarely acute renal failure (see section 4.5). As with any antihypertensive agent,excessive blood pressure decrease in patients with ischemic cardiopathy or ischemic cardiovascular<br />disease could result in a myocardial infarction or stroke.<br />Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of<br />allergy or bronchial asthma, but are more likely in patients with such a history.<br />Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide<br />diuretics.<br />Cases of photosensitivity reactions have been reported with thiazides diuretics (see section 4.8). If<br />photosensitivity reaction occurs during treatment, it is recommended to stop the treatment. If a readministration<br />of the diuretic is deemed necessary, it is recommended to protect exposed areas to the sun<br />or to artificial UVA.<br />Pregnancy: Angiotensin II Receptor Antagonists (AIIRAs) should not be initiated during pregnancy.<br />Unless continued AIIRA therapy is considered essential, patients planning pregnancy should be changed<br />to alternative antihypertensive treatments which have an established safety profile for use in pregnancy.<br />When pregnancy is diagnosed, treatment with AIIRAs should be stopped immediately, and, if<br />appropriate, alternative therapy should be started (see sections 4.3 and 4.6).<br />Lactose: this medicinal product contains lactose. Patients with rare hereditary problems of galactose<br />intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this<br />medicinal product.<br />Acute Myopia and Secondary Acute Angle-Closure Glaucoma: sulfonamide drugs or sulfonamide<br />derivative drugs can cause an idiosyncratic reaction, resulting in transient myopia and acute angle-closure<br />glaucoma. While hydrochlorothiazide is a sulfonamide, only isolated cases of acute angle-closure<br />glaucoma have been reported so far with hydrochlorothiazide. Symptoms include acute onset of<br />decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation.<br />Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to<br />discontinue drug intake as rapidly as possible. Prompt medical or surgical treatments may need to be<br />considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angleclosure<br />glaucoma may include a history of sulfonamide or penicillin allergy (see section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Other antihypertensive agents: the antihypertensive effect of Irbesartan and Hydrochlorothiazide may be<br />increased with the concomitant use of other antihypertensive agents. Irbesartan and hydrochlorothiazide<br />(at doses up to 300 mg Irbesartan/25 mg hydrochlorothiazide) have been safely administered with other<br />antihypertensive agents including calcium channel blockers and beta-adrenergic blockers. Prior treatment<br />with high dose diuretics may result in volume depletion and a risk of hypotension when initiating therapy<br />with Irbesartan with or without thiazide diuretics unless the volume depletion is corrected first (see<br />section 4.4).<br />Aliskiren-containing products or ACE-inhibitors: Clinical trial data has shown that dual blockade of the<br />renin-angiotensin-aldosterone system (RAAS) through the combined use of ACE-inhibitors, angiotensin<br />II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as<br />hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the<br />use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).<br />Lithium: reversible increases in serum lithium concentrations and toxicity have been reported during<br />concomitant administration of lithium with angiotensin converting enzyme inhibitors. Similar effects<br />have been very rarely reported with Irbesartan so far. Furthermore, renal clearance of lithium is reduced<br />by thiazides so the risk of lithium toxicity could be increased with Irbesartan and Hydrochlorothiazide.<br />Therefore, the combination of lithium and Irbesartan and Hydrochlorothiazide is not recommended (see<br />section 4.4). If the combination proves necessary, careful monitoring of serum lithium levels is<br />recommended.<br />Medicinal products affecting potassium: the potassium-depleting effect of hydrochlorothiazide is<br />attenuated by the potassium-sparing effect of Irbesartan. However, this effect of hydrochlorothiazide on<br />serum potassium would be expected to be potentiated by other medicinal products associated with<br />potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, amphotericin, carbenoxolone,<br />penicillin G sodium). Conversely, based on the experience with the use of other medicinal products that<br />blunt the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium<br />supplements, salt substitutes containing potassium or other medicinal products that may increase serum<br />potassium levels (e.g. heparin sodium) may lead to increases in serum potassium. Adequate monitoring<br />of serum potassium in patients at risk is recommended (see section 4.4).</p><p>Medicinal products affected by serum potassium disturbances: periodic monitoring of serum potassium is<br />recommended when Irbesartan and Hydrochlorothiazide is administered with medicinal products affected<br />by serum potassium disturbances (e.g. digitalis glycosides, antiarrhythmics).<br />Non-steroidal anti-inflammatory drugs: when angiotensin II antagonists are administered simultaneously<br />with non-steroidal anti- inflammatory drugs (i.e. selective COX-2 inhibitors, acetylsalicylic acid (&gt; 3<br />g/day) and non-selective NSAIDs), attenuation of the antihypertensive effect may occur.<br />As with ACE inhibitors, concomitant use of angiotensin II antagonists and NSAIDs may lead to an<br />increased risk of worsening of renal function, including possible acute renal failure, and an increase in<br />serum potassium, especially in patients with poor pre-existing renal function. The combination should be<br />administered with caution, especially in the elderly. Patients should be adequately hydrated and<br />consideration should be given to monitoring renal function after initiation of concomitant therapy, and<br />periodically thereafter.<br />Additional information on Irbesartan interactions: in clinical studies, the pharmacokinetic of Irbesartan is<br />not affected by hydrochlorothiazide. Irbesartan is mainly metabolised by CYP2C9 and to a lesser extent<br />by glucuronidation. No significant pharmacokinetic or pharmacodynamic interactions were observed<br />when Irbesartan was coadministered with warfarin, a medicinal product metabolised by CYP2C9. The<br />effects of CYP2C9 inducers such as rifampicin on the pharmacokinetic of Irbesartan have not been<br />evaluated. The pharmacokinetic of digoxin was not altered by co-administration of Irbesartan.<br />Additional information on hydrochlorothiazide interactions: when administered concurrently, the<br />following medicinal products may interact with thiazide diuretics:<br />Alcohol: potentiation of orthostatic hypotension may occur;<br />Antidiabetic medicinal products (oral agents and insulins): dosage adjustment of the antidiabetic<br />medicinal product may be required (see section 4.4);<br />Colestyramine and Colestipol resins: absorption of hydrochlorothiazide is impaired in the presence of<br />anionic exchange resins. Irbesartan and Hydrochlorothiazide should be taken at least one hour before or<br />four hours after these medications;<br />Corticosteroids, ACTH: electrolyte depletion, particularly hypokalaemia, may be increased;<br />Digitalis glycosides: thiazide induced hypokalaemia or hypomagnaesemia favour the onset of digitalisinduced<br />cardiac arrhythmias (see section 4.4);</p><p>Non-steroidal anti-inflammatory drugs: the administration of a non-steroidal anti-inflammatory drug may<br />reduce the diuretic, natriuretic and antihypertensive effects of thiazide diuretics in some patients;<br />Pressor amines (e.g. noradrenaline): the effect of pressor amines may be decreased, but not sufficiently<br />to preclude their use;<br />Nondepolarizing skeletal muscle relaxants (e.g. tubocurarine): the effect of nondepolarizing skeletal<br />muscle relaxants may be potentiated by hydrochlorothiazide;<br />Antigout medicinal products: dosage adjustments of antigout medicinal products may be necessary as<br />hydrochlorothiazide may raise the level of serum uric acid. Increase in dosage of probenecid or<br />sulfinpyrazone may be necessary. Co-administration of thiazide diuretics may increase the incidence of<br />hypersensitivity reactions to allopurinol;<br />Calcium salts: thiazide diuretics may increase serum calcium levels due to decreased excretion. If<br />calcium supplements or calcium sparing medicinal products (e.g. vitamin D therapy) must be prescribed,<br />serum calcium levels should be monitored and calcium dosage adjusted accordingly;<br />Carbamazepine: concomitant use of carbamazepine and hydrochlorothiazide has been associated with the<br />risk of symptomatic hyponatraemia. Electrolytes should be monitored during concomitant use. If<br />possible, another class of diuretics should be used;<br />Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by<br />thiazides. Anticholinergic agents (e.g. atropine, beperiden) may increase the bioavailability of thiazidetype<br />diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may increase<br />the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of cytotoxic<br />medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy:<br />Angiotensin II Receptor Antagonists (AIIRAs):<br />The use of AIIRAs is not recommended during the first trimester of pregnancy (see section 4.4). The use of<br />AIIRAs is contraindicated during the second and third trimesters of pregnancy (see sections 4.3 and 4.4).<br />Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors<br />during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot&nbsp;be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II Receptor<br />Antagonists (AIIRAs), similar risks may exist for this class of drugs. Unless continued AIIRA therapy is<br />considered essential, patients planning pregnancy should be changed to alternative antihypertensive<br />treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed,<br />treatment with AIIRAs should be stopped immediately, and, if appropriate, alternative therapy should be<br />started.<br />Exposure to AIIRA therapy during the second and third trimesters is known to induce human fetotoxicity<br />(decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal<br />failure, hypotension, hyperkalaemia). (See section 5.3).<br />Should exposure to AIIRAs have occurred from the second trimester of pregnancy, ultrasound check of<br />renal function and skull is recommended.<br />Infants whose mothers have taken AIIRAs should be closely observed for hypotension (see sections 4.3<br />and 4.4).<br />Hydrochlorothiazide:<br />There is limited experience with hydrochlorothiazide during pregnancy, especially during the first<br />trimester. Animal studies are insufficient. Hydrochlorothiazide crosses the placenta. Based on the<br />pharmacological mechanism of action of hydrochlorothiazide its use during the second and third<br />trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like<br />icterus, disturbance of electrolyte balance and thrombocytopenia.<br />Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia<br />due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on<br />the course of the disease.<br />Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare<br />situations where no other treatment could be used.<br />Since Irbesartan and Hydrochlorothiazide contains hydrochlorothiazide, it is not recommended during the<br />first trimester of pregnancy. A switch to a suitable alternative treatment should be carried out in advance<br />of a planned pregnancy.<br />Breast-feeding:<br />Angiotensin II Receptor Antagonists (AIIRAs):</p><p>Because no information is available regarding the use of Irbesartan and Hydrochlorothiazide during<br />breast-feeding, Irbesartan and Hydrochlorothiazide is not recommended and alternative treatments with<br />better established safety profiles during breast-feeding are preferable, especially while nursing a newborn<br />or preterm infant.<br />It is unknown whether Irbesartan or its metabolites are excreted in human milk.<br />Available pharmacodynamic/toxicological data in rats have shown excretion of Irbesartan or its<br />metabolites in milk (for details see 5.3).<br />Hydrochlorothiazide:<br />Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense<br />diuresis can inhibit the milk production. The use of Irbesartan and Hydrochlorothiazide during breast<br />feeding is not recommended. If Irbesartan and Hydrochlorothiazide is used during breast feeding, doses<br />should be kept as low as possible.<br />Fertility:<br />Irbesartan had no effect upon fertility of treated rats and their offspring up to the dose levels inducing the<br />first signs of parental toxicity (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. Based on its<br />pharmacodynamic properties, Irbesartan and Hydrochlorothiazide is unlikely to affect this ability. When<br />driving vehicles or operating machines, it should be taken into account that occasionally dizziness or<br />weariness may occur during treatment of hypertension.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Irbesartan/hydrochlorothiazide combination:<br />Among 898 hypertensive patients who received various doses of Irbesartan/hydrochlorothiazide (range:<br />37.5 mg/6.25 mg to 300 mg/25 mg) in placebo-controlled trials, 29.5% of the patients experienced<br />adverse reactions. The most commonly reported ADRs were dizziness (5.6%), fatigue (4.9%),<br />nausea/vomiting (1.8%), and abnormal urination (1.4%). In addition, increases in blood urea nitrogen<br />(BUN) (2.3%), creatine kinase (1.7%) and creatinine (1.1%) were also commonly observed in the trials.<br />Table 1 gives the adverse reactions observed from spontaneous reporting and in placebo-controlled trials.</p><p>The frequency of adverse reactions listed below is defined using the following convention:</p><p>very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1,000 to &lt; 1/100); rare (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="3" rowspan=""><p><strong>Table 1:</strong>&nbsp;Adverse Reactions in Placebo-Controlled Trials and Spontaneous Reports</p></td></tr><tr><td colspan="" rowspan="2"><p><em>Investigations:</em></p></td><td colspan="" rowspan=""><p>Common:</p></td><td colspan="" rowspan=""><p>increases in blood urea nitrogen (BUN), creatinine and creatine kinase</p></td></tr><tr><td colspan="" rowspan=""><p>Uncommon:</p></td><td colspan="" rowspan=""><p>decreases in serum potassium and sodium</p></td></tr><tr><td colspan="" rowspan=""><p><em>Cardiac disorders:</em></p></td><td colspan="" rowspan=""><p>Uncommon:</p></td><td colspan="" rowspan=""><p>syncope, hypotension, tachycardia, oedema</p></td></tr><tr><td colspan="" rowspan="3"><p><em>Nervous system disorders:</em></p></td><td colspan="" rowspan=""><p>Common:</p></td><td colspan="" rowspan=""><p>dizziness</p></td></tr><tr><td colspan="" rowspan=""><p>Uncommon:</p></td><td colspan="" rowspan=""><p>orthostatic dizziness</p></td></tr><tr><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>headache</p></td></tr><tr><td colspan="" rowspan=""><p><em>Ear and labyrinth disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>tinnitus</p></td></tr><tr><td colspan="" rowspan=""><p><em>Respiratory, thoracic and mediastinal disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>cough</p></td></tr><tr><td colspan="" rowspan="3"><p><em>Gastrointestinal disorders:</em></p></td><td colspan="" rowspan=""><p>Common:</p></td><td colspan="" rowspan=""><p>nausea/vomiting</p></td></tr><tr><td colspan="" rowspan=""><p>Uncommon:</p></td><td colspan="" rowspan=""><p>diarrhoea</p></td></tr><tr><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>dyspepsia, dysgeusia</p></td></tr><tr><td colspan="" rowspan="2"><p><em>Renal and urinary disorders:</em></p></td><td colspan="" rowspan=""><p>Common:</p></td><td colspan="" rowspan=""><p>abnormal urination</p></td></tr><tr><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>impaired renal function including isolated cases of renal failure in patients at risk (see section 4.4)</p></td></tr><tr><td colspan="" rowspan="2"><p><em>Musculoskeletal and connective tissue disorders:</em></p></td><td colspan="" rowspan=""><p>Uncommon:</p></td><td colspan="" rowspan=""><p>swelling extremity</p></td></tr><tr><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>arthralgia, myalgia</p></td></tr><tr><td colspan="" rowspan=""><p><em>Metabolism and nutrition disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>hyperkalaemia</p></td></tr><tr><td colspan="" rowspan=""><p><em>Vascular disorders:</em></p></td><td colspan="" rowspan=""><p>Uncommon:</p></td><td colspan="" rowspan=""><p>flushing</p></td></tr><tr><td colspan="" rowspan=""><p><em>General disorders and administration site conditions:</em></p></td><td colspan="" rowspan=""><p>Common:</p></td><td colspan="" rowspan=""><p>fatigue</p></td></tr><tr><td colspan="" rowspan=""><p><em>Immune system disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>cases of hypersensitivity reactions such as angioedema, rash, urticaria</p></td></tr><tr><td colspan="" rowspan=""><p><em>Hepatobiliary disorders:</em></p></td><td colspan="" rowspan=""><p>Uncommon:</p><p>Not known:</p></td><td colspan="" rowspan=""><p>jaundice</p><p>hepatitis, abnormal liver function</p></td></tr><tr><td colspan="" rowspan=""><p><em>Reproductive system and breast disorders:</em></p></td><td colspan="" rowspan=""><p>Uncommon:</p></td><td colspan="" rowspan=""><p>sexual dysfunction, libido changes</p></td></tr></tbody></table><p><u>Additional information on individual components:</u>&nbsp;in addition to the adverse reactions listed above for the combination product, other adverse reactions previously reported with one of the individual components may be potential adverse reactions with CoAprovel. Tables 2 and 3 below detail the adverse reactions reported with the individual components of CoAprovel.</p><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="3" rowspan=""><p><strong>Table 2:&nbsp;</strong>Adverse reactions reported with the use of&nbsp;<strong>irbesartan</strong>&nbsp;alone</p></td></tr><tr><td colspan="" rowspan=""><p><em>Blood and lymphatic system disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>thrombocytopenia</p></td></tr><tr><td colspan="" rowspan=""><p><em>General disorders and administration site conditions:</em></p></td><td colspan="" rowspan=""><p>Uncommon:</p></td><td colspan="" rowspan=""><p>chest pain</p></td></tr><tr><td colspan="" rowspan=""><p><em>Immune system disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>Anaphylactic reaction including anaphylactic shock</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="2" cellspacing="0" border="1" style="width:691px"><tbody><tr><td colspan="3" rowspan=""><p><strong>Table 3:</strong>&nbsp;Adverse reactions reported with the use of&nbsp;<strong>hydrochlorothiazide</strong>&nbsp;alone</p></td></tr><tr><td colspan="" rowspan=""><p><em>Investigations:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>electrolyte imbalance (including hypokalaemia and hyponatraemia, see section 4.4), hyperuricaemia, glycosuria, hyperglycaemia, increases in cholesterol and triglycerides</p></td></tr><tr><td colspan="" rowspan=""><p><em>Cardiac disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>cardiac arrhythmias</p></td></tr><tr><td colspan="" rowspan=""><p><em>Blood and lymphatic system disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>aplastic anaemia, bone marrow depression, neutropenia/agranulocytosis, haemolytic anaemia, leucopenia, thrombocytopenia</p></td></tr><tr><td colspan="" rowspan=""><p><em>Nervous system disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>vertigo, paraesthesia, light-headedness, restlessness</p></td></tr><tr><td colspan="" rowspan=""><p><em>Eye disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>transient blurred vision, xanthopsia, acute myopia and secondary acute angle-closure glaucoma</p></td></tr><tr><td colspan="" rowspan=""><p><em>Respiratory, thoracic and mediastinal disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>respiratory distress (including pneumonitis and pulmonary oedema)</p></td></tr><tr><td colspan="" rowspan=""><p><em>Gastrointestinal disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>pancreatitis, anorexia, diarrhoea, constipation, gastric irritation, sialadenitis, loss of appetite</p></td></tr><tr><td colspan="" rowspan=""><p><em>Renal and urinary disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>interstitial nephritis, renal dysfunction</p></td></tr><tr><td colspan="" rowspan=""><p><em>Skin and subcutaneous tissue disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>anaphylactic reactions, toxic epidermal necrolysis, necrotizing angitis (vasculitis, cutaneous vasculitis), cutaneous lupus erythematosus-like reactions, reactivation of cutaneous lupus erythematosus, photosensitivity reactions, rash, urticaria</p></td></tr><tr><td colspan="" rowspan=""><p><em>Musculoskeletal and connective tissue disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>weakness, muscle spasm</p></td></tr><tr><td colspan="" rowspan=""><p><em>Vascular disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>postural hypotension</p></td></tr><tr><td colspan="" rowspan=""><p><em>General disorders and administration site conditions:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>fever</p></td></tr><tr><td colspan="" rowspan=""><p><em>Hepatobiliary disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>jaundice (intrahepatic cholestatic jaundice)</p></td></tr><tr><td colspan="" rowspan=""><p><em>Psychiatric disorders:</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>depression, sleep disturbances</p></td></tr><tr><td colspan="" rowspan=""><p><em>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</em></p></td><td colspan="" rowspan=""><p>Not known:</p></td><td colspan="" rowspan=""><p>non-melanoma skin cancer (basal cell carcinoma and squamous cell carcinoma)</p></td></tr></tbody></table><p>Non-melanoma skin cancer: Based on available data from epidemiological studies, cumulative dose dependent association between HCTZ and NMSC has been observed (see also sections 4.4 and 5.1).</p><p>The dose dependent adverse events of hydrochlorothiazide (particularly electrolyte disturbances) may increase when titrating the hydrochlorothiazide.</p><p>Reporting of suspected adverse reactions<br />To report any side effect(s):<br />Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety Centre (NPC)<br />Fax: +966-11-205-7662.<br />Call NPC at +966-11-2038222,<br />Exts: 2317-2356-2353-2354-2334-2340.<br />Toll free phone: 8002490000<br />E-mail: npc.drug@sfda.gov.sa<br />Website: www.sfda.gov.sa/npc<br />Other GCC States:<br />Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific information is available on the treatment of overdose with Irbesartan and<br />Hydrochlorothiazide. The patient should be closely monitored, and the treatment should be symptomatic<br />and supportive. Management depends on the time since ingestion and the severity of the symptoms.</p><p>Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful<br />in the treatment of overdose. Serum electrolytes and creatinine should be monitored frequently. If<br />hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements<br />given quickly.<br />The most likely manifestations of Irbesartan overdose are expected to be hypotension and tachycardia;<br />bradycardia might also occur.<br />Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia,<br />hypochloremia, hyponatraemia) and dehydration resulting from excessive diuresis. The most common<br />signs and symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasms<br />and/or accentuate cardiac arrhythmias associated with the concomitant use of digitalis glycosides or<br />certain anti-arrhythmic medicinal products.<br />Irbesartan is not removed by haemodialysis. The degree to which hydrochlorothiazide is removed by<br />haemodialysis has not been established.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Pharmacotherapeutic group: angiotensin-II antagonists, combinations<br />ATC code: C09DA04.<br />Irbesartan and Hydrochlorothiazide is a combination of an angiotensin-II receptor antagonist, Irbesartan,<br />and a thiazide diuretic, hydrochlorothiazide. The combination of these ingredients has an additive<br />antihypertensive effect, reducing blood pressure to a greater degree than either component alone.<br />Irbesartan is a potent, orally active, selective angiotensin-II receptor (AT1 subtype) antagonist. It is<br />expected to block all actions of angiotensin-II mediated by the AT1 receptor, regardless of the source or<br />route of synthesis of angiotensin-II. The selective antagonism of the angiotensin-II (AT1) receptors<br />results in increases in plasma renin levels and angiotensin-II levels, and a decrease in plasma aldosterone<br />concentration. Serum potassium levels are not significantly affected by Irbesartan alone at the<br />recommended doses in patients without risk of electrolyte imbalance (see sections 4.4 and 4.5). Irbesartan<br />does not inhibit ACE (kininase-II), an enzyme which generates angiotensin-II and also degrades<br />bradykinin into inactive metabolites. Irbesartan does not require metabolic activation for its activity.</p><p style="text-align:justify">Hydrochlorothiazide is a thiazide diuretic. The mechanism of antihypertensive effect of thiazide diuretics<br />is not fully known. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly<br />increasing excretion of sodium and chloride in approximately equivalent amounts. The diuretic action of<br />hydrochlorothiazide reduces plasma volume, increases plasma renin activity, increases aldosterone<br />secretion, with consequent increases in urinary potassium and bicarbonate loss, and decreases in serum<br />potassium. Presumably through blockade of the renin-angiotensin-aldosterone system, co-administration<br />of Irbesartan tends to reverse the potassium loss associated with these diuretics. With<br />hydrochlorothiazide, onset of diuresis occurs in 2 hours, and peak effect occurs at about 4 hours, while<br />the action persists for approximately 6-12 hours.<br />The combination of hydrochlorothiazide and Irbesartan produces dose-related additive reductions in<br />blood pressure across their therapeutic dose ranges. The addition of 12.5 mg hydrochlorothiazide to 300<br />mg Irbesartan once daily in patients not adequately controlled on 300 mg Irbesartan alone resulted in<br />further placebo-corrected diastolic blood pressure reductions at trough (24 hours post-dosing) of 6.1 mm<br />Hg. The combination of 300 mg Irbesartan and 12.5 mg hydrochlorothiazide resulted in an overall<br />placebo-subtracted systolic/diastolic reductions of up to 13.6/11.5 mm Hg.<br />Limited clinical data (7 out of 22 patients) suggest that patients not controlled with the 300 mg/12.5 mg<br />combination may respond when uptitrated to 300 mg/25 mg. In these patients, an incremental blood<br />pressure lowering effect was observed for both systolic blood pressure (SBP) and diastolic blood pressure<br />(DBP) (13.3 and 8.3 mm Hg, respectively).<br />Once daily dosing with 150 mg Irbesartan and 12.5 mg hydrochlorothiazide gave systolic/diastolic mean<br />placebo-adjusted blood pressure reductions at trough (24 hours post-dosing) of 12.9/6.9 mm Hg in<br />patients with mild-to-moderate hypertension. Peak effects occurred at 3-6 hours. When assessed by<br />ambulatory blood pressure monitoring, the combination 150 mg Irbesartan and 12.5 mg<br />hydrochlorothiazide once daily produced consistent reduction in blood pressure over the 24 hours period<br />with mean 24-hour placebo-subtracted systolic/diastolic reductions of 15.8/10.0 mm Hg. When measured<br />by ambulatory blood pressure monitoring, the trough to peak effects of Irbesartan and<br />Hydrochlorothiazide 150 mg/12.5 mg were 100%. The trough to peak effects measured by cuff during<br />office visits were 68% and 76% for Irbesartan and Hydrochlorothiazide 150 mg/12.5 mg and Irbesartan<br />and Hydrochlorothiazide 300 mg/12.5 mg, respectively. These 24-hour effects were observed without&nbsp;excessive blood pressure lowering at peak and are consistent with safe and effective blood-pressure<br />lowering over the once-daily dosing interval.<br />In patients not adequately controlled on 25 mg hydrochlorothiazide alone, the addition of Irbesartan gave<br />an added placebo-subtracted systolic/diastolic mean reduction of 11.1/7.2 mm Hg.<br />The blood pressure lowering effect of Irbesartan in combination with hydrochlorothiazide is apparent<br />after the first dose and substantially present within 1-2 weeks, with the maximal effect occurring by 6-8<br />weeks. In long-term follow-up studies, the effect of Irbesartan/hydrochlorothiazide was maintained for<br />over one year. Although not specifically studied with the Irbesartan and Hydrochlorothiazide, rebound<br />hypertension has not been seen with either Irbesartan or hydrochlorothiazide.<br />The effect of the combination of Irbesartan and hydrochlorothiazide on morbidity and mortality has not<br />been studied. Epidemiological studies have shown that long term treatment with hydrochlorothiazide<br />reduces the risk of cardiovascular mortality and morbidity.<br />There is no difference in response to Irbesartan and Hydrochlorothiazide, regardless of age or gender. As<br />is the case with other medicinal products that affect the renin-angiotensin system, black hypertensive<br />patients have notably less response to Irbesartan monotherapy. When Irbesartan is administered<br />concomitantly with a low dose of hydrochlorothiazide (e.g. 12.5 mg daily), the antihypertensive response<br />in black patients approaches that of non-black patients.<br />Efficacy and safety of Irbesartan and Hydrochlorothiazide as initial therapy for severe hypertension<br />(defined as SeDBP &ge; 110 mmHg) was evaluated in a multicenter, randomized, double-blind, activecontrolled,<br />8-week, parallel-arm study. A total of 697 patients were randomized in a 2:1 ratio to either<br />Irbesartan/hydrochlorothiazide 150 mg/12.5 mg or to Irbesartan 150 mg and systematically force-titrated<br />(before assessing the response to the lower dose) after one week to Irbesartan/hydrochlorothiazide 300<br />mg/25 mg or Irbesartan 300 mg, respectively.<br />The study recruited 58% males. The mean age of patients was 52.5 years, 13% were &ge; 65 years of age,<br />and just 2% were &ge; 75 years of age. Twelve percent (12%) of patients were diabetic, 34% were<br />hyperlipidemic and the most frequent cardiovascular condition was stable angina pectoris in 3.5% of the<br />participants.<br />The primary objective of this study was to compare the proportion of patients whose SeDBP was<br />controlled (SeDBP &lt; 90 mmHg) at Week 5 of treatment. Forty-seven percent (47.2%) of patients on the&nbsp;combination achieved trough SeDBP &lt; 90 mmHg compared to 33.2% of patients on Irbesartan (p =<br />0.0005). The mean baseline blood pressure was approximately 172/113 mmHg in each treatment group<br />and decreases of SeSBP/SeDBP at five weeks were 30.8/24.0 mmHg and 21.1/19.3 mmHg for<br />Irbesartan/hydrochlorothiazide and Irbesartan, respectively (p &lt; 0.0001).<br />The types and incidences of adverse events reported for patients treated with the combination were<br />similar to the adverse event profile for patients on monotherapy. During the 8-week treatment period,<br />there were no reported cases of syncope in either treatment group. There were 0.6% and 0% of patients<br />with hypotension and 2.8% and 3.1% of patients with dizziness as adverse reactions reported in the<br />combination and monotherapy groups, respectively.<br />Dual blockade of the renin-angiotensin-aldosterone system (RAAS)<br />Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination<br />with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in<br />Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor<br />blocker. ONTARGET was a study conducted in patients with a history of cardiovascular or<br />cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA<br />NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.<br />These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and<br />mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared<br />to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also<br />relevant for other ACE-inhibitors and angiotensin II receptor blockers.<br />ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in<br />patients with diabetic nephropathy.<br />ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was<br />a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an<br />angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease,<br />cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse<br />outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group<br />than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia,&nbsp;hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the<br />placebo group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Concomitant administration of hydrochlorothiazide and Irbesartan has no effect on the pharmacokinetics<br />of either medicinal product.<br />Irbesartan and hydrochlorothiazide are orally active agents and do not require biotransformation for their<br />activity. Following oral administration of Irbesartan and Hydrochlorothiazide, the absolute oral<br />bioavailability is 60-80% and 50-80% for Irbesartan and hydrochlorothiazide, respectively. Food does<br />not affect the bioavailability of Irbesartan and Hydrochlorothiazide. Peak plasma concentration occurs at<br />1.5-2 hours after oral administration for Irbesartan and 1-2.5 hours for hydrochlorothiazide.<br />Plasma protein binding of Irbesartan is approximately 96%, with negligible binding to cellular blood<br />components. The volume of distribution for Irbesartan is 53-93 litres. Hydrochlorothiazide is 68%<br />protein-bound in the plasma, and its apparent volume of distribution is 0.83-1.14 l/kg.<br />Irbesartan exhibits linear and dose proportional pharmacokinetics over the dose range of 10 to 600 mg. A<br />less than proportional increase in oral absorption at doses beyond 600 mg was observed; the mechanism<br />for this is unknown. The total body and renal clearance are 157-176 and 3.0-3.5 ml/min, respectively.<br />The terminal elimination half-life of Irbesartan is 11-15 hours. Steady-state plasma concentrations are<br />attained within 3 days after initiation of a once-daily dosing regimen. Limited accumulation of Irbesartan<br />(&lt; 20%) is observed in plasma upon repeated once-daily dosing. In a study, somewhat higher plasma<br />concentrations of Irbesartan were observed in female hypertensive patients. However, there was no<br />difference in the half-life and accumulation of Irbesartan. No dosage adjustment is necessary in female<br />patients. Irbesartan AUC and Cmax values were also somewhat greater in older subjects (&ge; 65 years) than<br />those of young subjects (18-40 years). However the terminal half-life was not significantly altered. No<br />dosage adjustment is necessary in older people. The mean plasma half-life of hydrochlorothiazide<br />reportedly ranges from 5-15 hours.<br />Following oral or intravenous administration of 14C Irbesartan, 80-85% of the circulating plasma<br />radioactivity is attributable to unchanged Irbesartan. Irbesartan is metabolised by the liver via<br />glucuronide conjugation and oxidation. The major circulating metabolite is Irbesartan glucuronide<br />(approximately 6%). In vitro studies indicate that Irbesartan is primarily oxidised by the cytochrome&nbsp;P450 enzyme CYP2C9; isoenzyme CYP3A4 has negligible effect. Irbesartan and its metabolites are<br />eliminated by both biliary and renal pathways. After either oral or intravenous administration of 14C<br />Irbesartan, about 20% of the radioactivity is recovered in the urine, and the remainder in the faeces. Less<br />than 2% of the dose is excreted in the urine as unchanged Irbesartan. Hydrochlorothiazide is not<br />metabolized but is eliminated rapidly by the kidneys. At least 61% of the oral dose is eliminated<br />unchanged within 24 hours. Hydrochlorothiazide crosses the placental but not the blood-brain barrier,<br />and is excreted in breast milk.<br />Renal impairment: in patients with renal impairment or those undergoing haemodialysis, the<br />pharmacokinetic parameters of Irbesartan are not significantly altered. Irbesartan is not removed by<br />haemodialysis. In patients with creatinine clearance &lt; 20 ml/min, the elimination half-life of<br />hydrochlorothiazide was reported to increase to 21 hours.<br />Hepatic impairment: in patients with mild to moderate cirrhosis, the pharmacokinetic parameters of<br />Irbesartan are not significantly altered. Studies have not been performed in patients with severe hepatic<br />impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Irbesartan/hydrochlorothiazide: the potential toxicity of the Irbesartan/hydrochlorothiazide combination<br />after oral administration was evaluated in rats and macaques in studies lasting up to 6 months. There<br />were no toxicological findings observed of relevance to human therapeutic use.<br />The following changes, observed in rats and macaques receiving the Irbesartan/hydrochlorothiazide<br />combination at 10/10 and 90/90 mg/kg/day, were also seen with one of the two medicinal products alone<br />and/or were secondary to decreases in blood pressure (no significant toxicologic interactions were<br />observed):<br />&bull; kidney changes, characterized by slight increases in serum urea and creatinine, and<br />hyperplasia/hypertrophy of the juxtaglomerular apparatus, which are a direct consequence of the<br />interaction of Irbesartan with the renin-angiotensin system;<br />&bull; slight decreases in erythrocyte parameters (erythrocytes, haemoglobin, haematocrit);<br />&bull; stomach discoloration, ulcers and focal necrosis of gastric mucosa were observed in few rats in a 6<br />months toxicity study at Irbesartan 90 mg/kg/day, hydrochlorothiazide 90 mg/kg/day, and<br />Irbesartan/hydrochlorothiazide 10/10 mg/kg/day. These lesions were not observed in macaques;</p><p>&bull; decreases in serum potassium due to hydrochlorothiazide and partly prevented when<br />hydrochlorothiazide was given in combination with Irbesartan.<br />Most of the above mentioned effects appear to be due to the pharmacological activity of Irbesartan<br />(blockade of angiotensin-II-induced inhibition of renin release, with stimulation of the renin-producing<br />cells) and occur also with angiotensin converting enzyme inhibitors. These findings appear to have no<br />relevance to the use of therapeutic doses of Irbesartan/hydrochlorothiazide in humans.<br />No teratogenic effects were seen in rats given Irbesartan and hydrochlorothiazide in combination at doses<br />that produced maternal toxicity. The effects of the Irbesartan/hydrochlorothiazide combination on fertility<br />have not been evaluated in animal studies, as there is no evidence of adverse effect on fertility in animals<br />or humans with either Irbesartan or hydrochlorothiazide when administered alone. However, another<br />angiotensin-II antagonist affected fertility parameters in animal studies when given alone. These findings<br />were also observed with lower doses of this other angiotensin-II antagonist when given in combination<br />with hydrochlorothiazide.<br />There was no evidence of mutagenicity or clastogenicity with the Irbesartan/hydrochlorothiazide<br />combination. The carcinogenic potential of Irbesartan and hydrochlorothiazide in combination has not<br />been evaluated in animal studies.<br />Irbesartan: there was no evidence of abnormal systemic or target organ toxicity at clinically relevant<br />doses. In non-clinical safety studies, high doses of Irbesartan (&ge; 250 mg/kg/day in rats and &ge; 100<br />mg/kg/day in macaques) caused a reduction of red blood cell parameters (erythrocytes, haemoglobin,<br />haematocrit). At very high doses (&ge; 500 mg/kg/day) degenerative changes in the kidneys (such as<br />interstitial nephritis, tubular distention, basophilic tubules, increased plasma concentrations of urea and<br />creatinine) were induced by Irbesartan in the rat and the macaque and are considered secondary to the<br />hypotensive effects of the medicinal product which led to decreased renal perfusion. Furthermore,<br />Irbesartan induced hyperplasia/hypertrophy of the juxtaglomerular cells (in rats at &ge; 90 mg/kg/day, in<br />macaques at &ge; 10 mg/kg/day). All of these changes were considered to be caused by the pharmacological<br />action of Irbesartan. For therapeutic doses of Irbesartan in humans, the hyperplasia/hypertrophy of the<br />renal juxtaglomerular cells does not appear to have any relevance.<br />There was no evidence of mutagenicity, clastogenicity or carcinogenicity.</p><p>Fertility and reproductive performance were not affected in studies of male and female rats even at oral<br />doses of Irbesartan causing some parental toxicity (from 50 to 650 mg/kg/day), including mortality at the<br />highest dose. No significant effects on the number of corpora lutea, implants, or live fetuses were<br />observed. Irbesartan did not affect survival, development, or reproduction of offspring. Studies in animals<br />indicate that the radiolabeled Irbesartan is detected in rat and rabbit fetuses. Irbesartan is excreted in the<br />milk of lactating rats.<br />Animal studies with Irbesartan showed transient toxic effects (increased renal pelvic cavitation,<br />hydroureter or subcutaneous oedema) in rat foetuses, which were resolved after birth. In rabbits, abortion<br />or early resorption was noted at doses causing significant maternal toxicity, including mortality. No<br />teratogenic effects were observed in the rat or rabbit.<br />Hydrochlorothiazide: although equivocal evidence for a genotoxic or carcinogenic effect was found in<br />some experimental models, the extensive human experience with hydrochlorothiazide has failed to show<br />an association between its use and an increase in neoplasms.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Core:<br /> Lactose Monohydrate<br /> Microcrystalline Cellulose PH 101<br /> Pregelatinized Starch &ndash; 1500<br /> Croscarmellose Sodium<br /> Purified Water<br /> Microcrystalline Cellulose PH 102<br /> Magnesium Stearate<br />Coating:<br /> Opadry II 32F265003 Pink which is consists of HPMC 2910/Hypromellose ,Lactose<br />Monohydrate, Titanium Dioxide, Macrogol/Polyethylene glycol (PEG), Iron Oxide Red and<br />Ferrosoferric Oxide)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 Years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <ul><li>Do not store above 30&deg;C.</li><li>Store in the original package in order to protect from moisture.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Arena Plus 300/25 mg Film Coated is packed in Aluminium foil and Opaque PVC /PVDC, Blister<br />pack of 3x10&rsquo;s.<br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>---</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
Plot No. ME 1:3, Phase V, Industrial City, Jeddah
Postal address:
P.O. Box 6267
Jeddah 21442, Saudi Arabia.
Tel: 00966-12-6081111
Fax: 00966-12-6081222
E-mail: jpharma@jamjoompharma.com
Website: www.jamjoompharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aug-2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>